Pfizer changes convention for virus vaccine: study Kumar Jeetendra | October 13, 2020 Drugmaker Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company said on Monday that it’s received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study. New York-based Pfizer …
Pfizer, BioNTech start consolidated preliminaries of COVID-19 immunization candidate in Japan Kumar Jeetendra | October 20, 2020 Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of the mRNA vaccine candidate against the coronavirus. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021. Pfizer, which is developing …
Pfizer, AstraZeneca vaccines secure against Delta variant: Lancet study Kumar Jeetendra | June 15, 2021 The Delta variant of coronavirus, first identified in India, doubles the risk of hospitalisation compared with the Alpha variant first found in the UK, but Pfizer and AstraZeneca vaccines provide good protection against the strain, says a study published in The Lancet journal. Researchers at Public Health Scotland and the University of Edinburgh, UK, found …
